Journal of Shanghai Jiao Tong University (Medical Science) >
Features of oral peripheral T-cell lymphoma, not otherwise specified
Received date: 2024-11-07
Accepted date: 2025-02-24
Online published: 2025-05-28
Supported by
Shanghai Municipal Commission of Science and Technology Fund(21S21902000);Shanghai Municipal Commission of Health Fund [(ZY(2021-2023)- 0207-01-04, 2022CX009)];Cross Project Cooperation Fund of Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine(JYJC202111)
Objective ·To investigate the clinical manifestations and immunophenotypic features of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), involving the oral cavity. Methods ·The medical histories and pathology records of patients diagnosed with oral PTCL-NOS in the Department of Oral Mucosal Diseases of Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, between August 2020 and August 2024 were retrospectively analyzed. In addition, 5 databases, including PubMed, Web of Science, Embase, Scopus, and CNKI, were searched, and relevant cases reported internationally from January 2014 to September 2024 were reviewed. Results ·A total of 20 oral PTCL-NOS cases were included, comprising 11 males (55.0%) and 9 females (45.0%). The patients′ ages at initial diagnosis ranged from 25 to 77 years, with a mean age of (52.53±12.94) years. The most common sites were the tongue (25.0%), palate (25.0%), and buccal mucosa (20.0%). Nineteen cases (95.0%) had no B symptoms. The cases were positive for CD3 (19/19), CD4 (11/13), CD8 (7/12), CD2 (5/6), CD7 (5/5), TIA-1 (6/7), GB (9/13), perforin (4/6). EBER expression was negative (8/8). The Ki-67 proliferation index was ≥60% in 85% of cases. Conclusions ·Oral PTCL-NOS is extremely rare and has an aggressive clinical behavior. The oral manifestation presents as deep and large mucosal ulcers with uneven bases, and nodules can be palpable. The pathological features are heterogeneous. Immunophenotype detection is useful for early diagnosis and classification. It is essential for stomatologists to enhance their awareness of this malignancy to avoid delayed diagnosis and treatment.
HUANG Runyu , ZHANG Chunye , ZHANG Ying , ZHAO Zhengyan , YANG Yang , WU Lan . Features of oral peripheral T-cell lymphoma, not otherwise specified[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025 , 45(5) : 653 -660 . DOI: 10.3969/j.issn.1674-8115.2025.05.015
1 | SWERDLOW S H, CAMPO E, HARRIS N L, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Revised 4th ed. Lyon: IARC Press, 2017. |
2 | LEE J H, LEE S H. A poor prognostic case of peripheral T-cell lymphoma in the base of tongue with chemotherapy followed by radiation therapy[J]. Springerplus, 2014, 3: 731. |
3 | NARLA S, ANNAPURNESWARI S, PARAMESWARAN A, et al. Peripheral T-cell lymphoma of tongue: report of a rare case and review of literature[J]. J Oral Maxillofac Pathol, 2016, 20(2): 332. |
4 | 薛敏, 高冶, 段介君. 以舌部肿物为表现的外周型T细胞淋巴瘤1例[J]. 宁夏医科大学学报, 2017, 39(1): 115-116. |
XUE M, GAO Y, DUAN J J. A case of peripheral T-cell lymphoma presenting as a tongue mass[J]. Journal of Ningxia Medical University, 2017, 39(1): 115-116. | |
5 | DOS SANTOS H L R, ALVES C G B, ALMENDRA MATTOS R M, et al. Peripheral T-cell non-Hodgkin lymphoma manifesting as a primary lesion on the lip: a rare case report[J]. Spec Care Dentist, 2018, 38(6): 438-444. |
6 | REN X Y, CHENG Y, WU S F, et al. Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV status[J]. Diagn Pathol, 2020, 15(1): 30. |
7 | ALMEIDA DE ARRUDA J A, DE CASTRO ABRANTES T, CUNHA J L S, et al. Mature T/NK-cell lymphomas of the oral and maxillofacial region: a multi-institutional collaborative study[J]. J Oral Pathol Med, 2021, 50(6): 548-557. |
8 | ASADI A A, MAHMOUDI H, MOFIDI A, et al. Peripheral T-cell lymphoma of the oral cavity: a case report[J]. Cancer Rep (Hoboken), 2023, 6(1): e1751. |
9 | DE OLIVEIRA E M, DE CáCERES C V B L, FERNANDES-RODRIGUES C I, et al. Oral manifestations of peripheral T cell lymphoma, not otherwise specified: case series and review of the current literature[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2025, 139(2): e37-e45. |
10 | PILERI S A, TABANELLI V, FIORI S, et al. Peripheral T-cell lymphoma, not otherwise specified: clinical manifestations, diagnosis, and future treatment[J]. Cancers (Basel), 2021, 13(18): 4535. |
11 | COSTELLO R, SANCHEZ C, LE TREUT T, et al. Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations[J]. Br J Haematol, 2010, 150(1): 21-27. |
12 | LUO J J, CRAVER A, BAHL K, et al. Etiology of non-Hodgkin lymphoma: a review from epidemiologic studies[J]. J Natl Cancer Cent, 2022, 2(4): 226-234. |
13 | COCCO P, VERMEULEN R, FLORE V, et al. Occupational exposure to trichloroethylene and risk of non-Hodgkin lymphoma and its major subtypes: a pooled InterLymph analysis[J]. Occup Environ Med, 2013, 70(11): 795-802. |
14 | BASSIG B A, SHU X O, FRIESEN M C, et al. Occupational exposure to benzene and risk of non-Hodgkin lymphoma in an extended follow-up of two population-based prospective cohorts of Chinese men and women[J]. Int J Cancer, 2024, 155(12): 2159-2168. |
15 | BRYER E, HENRY D. Isolated hypoglossal nerve palsy as a presenting symptom of metastatic peripheral T-cell lymphoma - not otherwise specified (PTCL-NOS): a unique case & a review of the literature[J]. Int J Hematol Oncol, 2018, 7(1): IJH03. |
16 | SCHMITZ N, DE LEVAL L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future[J]. Br J Haematol, 2017, 176(6): 851-866. |
17 | WENT P, AGOSTINELLI C, GALLAMINI A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score[J]. J Clin Oncol, 2006, 24(16): 2472-2479. |
18 | LIM S T, HEE S W, QUEK R, et al. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis[J]. Eur J Haematol, 2008, 80(1): 55-60. |
19 | D′AMORE F, GAULARD P, TRüMPER L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2015, 26(Suppl 5): v108-v115. |
20 | SHEN Q D, WANG L, ZHU H Y, et al. Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma[J]. J Cancer, 2021, 12(1): 163-169. |
21 | MINA A, PRO B. T time: emerging and new therapies for peripheral T-cell lymphoma[J]. Blood Rev, 2022, 52: 100889. |
22 | 李静, 李志铭. 外周T细胞淋巴瘤和结外NK/T细胞淋巴瘤研究进展[J]. 肿瘤药学, 2024, 14(1): 16-21. |
LI J, LI Z M. Research progress of peripheral T-cell lymphoma and extranodal NK/T-cell lymphoma [J]. Anti-tumor Pharmacy, 2024, 14(1): 16-21. |
/
〈 |
|
〉 |